We are live on ! Find out more
CYTO icon

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

4 hedge funds and large institutions have $2.95K invested in Altamira Therapeutics Ltd in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

33% more funds holding

Funds holding: 3 → 4 (+1)

18% more capital inflows, than outflows

Capital inflows: $4.05K | Capital outflows: $3.44K

0.06% more ownership

Funds ownership: 0.11% → 0.17% (+0.06%)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$2.62K
2
Morgan Stanley
Morgan Stanley
New York
+$1.43K

Top Sellers

Rank Fund Capital Flow
1
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$3.44K

CYTO Hedge Fund Activity: Q2 2024 in Review

4 of the 6,944 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q2 2024, worth a combined $2.95K — down 15% from $3.47K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CYTO positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $2.62K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.44K sold.

  • 4 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q2 2024, up from 3 in Q1 2024.
  • Funds reported $2.95K of Altamira Therapeutics Ltd stock for Q2 2024, down 15% quarter-over-quarter.
  • 2 funds opened new Altamira Therapeutics Ltd positions in Q2 2024 and 1 closed out, a net change of +1 holder.
  • The largest Altamira Therapeutics Ltd buyer in Q2 2024 was UBS Group, an estimated $2.62K added.
  • The largest Altamira Therapeutics Ltd seller in Q2 2024 was Tower Research Capital (TRC), an estimated $3.44K sold.

Based on aggregated 13F filings for Q2 2024.